www.jtocrr.org/article/S266...

#lcsm #nsclc #zongertinib #tdxd #lungcancer

Synapse: Your Connection to our MSK Authors
Meet: Mithat Gonen
Research Focus: Biostat/Epidemiology; Attending

Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer
synapse.mskcc.org/synapse/work...

#HER2Positive #MetastaticBreastCancer
#TDXd #BreastCancerResearch

Sage Journals: Discover world-class research Subscription and open access journals from Sage, the world's leading independent academic publisher.

📢 Real-world data from China on T-DXd in HER2+ and HER2-low advanced breast cancer is here!
🧬 PFS ~10 months
📈 ORR: 62.5% (HER2+) | 37.9% (HER2-low)
✅ Manageable safety profile
T-DXd shows promise across HER2 expression levels. buff.ly/jrOE20b
#BreastCancer #HER2 #Oncology #RealWorldEvidence #TDXd

Primary results from a phase 2a study show #Zanidatamab + #Palbociclib + #Fulvestrant is a promising chemotherapy-free option for heavily pretreated HR+/HER2+ MBC patients.

@thelancetoncol.bsky.social

#Onco404 #Cancer #Kanser #BreastCancer #ClinicalTrials #HER2 #ADC #TDXd #Healthcare #Innovation

Sarah Sammons Comments on TDXd Use in Early HER2+ Breast Cancer - OncoDaily Sarah Sammons shares perspective on neoadjuvant TDXd use in HER2-positive breast cancer.

Sarah Sammons Comments on TDXd Use in Early HER2+ Breast Cancer
@drsarahsammons.bsky.social @erikahamilton9.bsky.social

oncodaily.com/blog/tdxd-29...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TDXd #HER2 #BreastCancer

Olubukola Ayodele: Discussing T-DXd toxicities in breast cancer at a thought-provoking meeting in Lisbon - OncoDaily Olubukola Ayodele shares insights from a Lisbon meeting on managing T-DXd toxicities in metastatic HER2-positive breast cancer.

Discussing T-DXd toxicities in breast cancer at a thought-provoking meeting in Lisbon - Olubukola Ayodele
@bookiephronesis.bsky.social

oncodaily.com/blog/olubuko...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lisbon #BreastCancer #TDXd

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer - Breast Cancer Research Background Trastuzumab deruxtecan (T-DXd) is FDA-approved for treatment of patients with HER2 positive and HER2-low metastatic breast cancer. Currently, there is limited understanding of pre-treatment...

Happy to share our retrospective study on #pneumonitis risk in patients with #breastcancer who receive #TDXd #Enhertu @stoverlab.bsky.social @osucccjames.bsky.social #bcsm

Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies

DB-06 #TDXD approved for HER-2 "ultra low" (IHC but staining) breast cancer, and 1st line moving this drug up.

#bcsm
@oncoalert.bsky.social

www.astrazeneca.com/media-centre...